Glucagon-like peptide-1 receptor agonists tied to higher thyroid cancer risk in first year of treatment

by

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a study published online Jan. 23 in JAMA Otolaryngology-Head & Neck Surgery.

Leave A Comment

Your email address will not be published. Required fields are marked *